Key Points
- Insider sale: Traci Umberger sold 10,500 shares on Dec. 29 at an average price of $26.69 for $280,245, trimming her stake by 7.14% to 136,633 shares (valued at about $3.65M); the trade was disclosed in an SEC filing.
- Kestra Medical (KMTS) is trading near $26.50 with a 52-week range of $13.25–$30.00, a market cap of roughly $1.55 billion and a negative PE of -8.37.
- Analyst backdrop: The consensus is a "Moderate Buy" with a $29.14 target; several firms (Piper Sandler, Stifel) have raised targets to $30 while others (Weiss, Wall Street Zen) remain bearish.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Traci Umberger sold 10,500 shares of the business's stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider owned 136,633 shares of the company's stock, valued at $3,646,734.77. This trade represents a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Kestra Medical Technologies Trading Down 1.7%
Shares of KMTS stock opened at $26.52 on Thursday. Kestra Medical Technologies, Ltd. has a 52-week low of $13.25 and a 52-week high of $30.00. The business's fifty day moving average is $26.30 and its 200 day moving average is $21.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. The company has a market capitalization of $1.55 billion and a PE ratio of -8.37.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Piper Sandler boosted their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, December 12th. Wall Street Zen cut Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research note on Sunday, September 28th. Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a research note on Friday, December 12th. The Goldman Sachs Group raised their price objective on Kestra Medical Technologies from $22.00 to $25.00 and gave the company a "neutral" rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.
View Our Latest Research Report on KMTS
Institutional Investors Weigh In On Kestra Medical Technologies
Several institutional investors have recently bought and sold shares of KMTS. Quarry LP bought a new position in Kestra Medical Technologies during the 1st quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies in the third quarter worth approximately $48,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Kestra Medical Technologies in the second quarter worth $54,000. BNP Paribas Financial Markets raised its holdings in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its position in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock valued at $74,000 after buying an additional 656 shares during the period.
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
